Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €1.62 EUR
Change Today -0.117 / -6.74%
Volume 5.4K
As of 3:24 AM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).

evolva holding sa (ADF) Snapshot

Open
€1.65
Previous Close
€1.74
Day High
€1.69
Day Low
€1.62
52 Week High
03/30/15 - €1.74
52 Week Low
10/16/14 - €0.88
Market Cap
530.7M
Average Volume 10 Days
3.2K
EPS TTM
--
Shares Outstanding
327.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EVOLVA HOLDING SA (ADF)

Related News

No related news articles were found.

evolva holding sa (ADF) Related Businessweek News

No Related Businessweek News Found

evolva holding sa (ADF) Details

Evolva Holding SA, a biosynthetic company, discovers and develops ingredients and processes for nutrition, health care, and wellness products in Switzerland and internationally. Its technologies are based on yeast that is used in the production of food and beverages. The company’s principal products include Resveratrol, a natural compound produced in grapes and other plants as a response against environmental stress factors; Stevia, a leafy green plant used as natural, zero-calorie, high-and intensity sweetener forms in beverages; Vanilla, a complex blend of flavour and fragrance compounds extracted from the seed pods of the vanilla orchid; Saffron, a spice for food coloring and flavoring, as well as for its aroma properties; and Pomecins that prevent mould and yeast growth. It also offers EV-077, a reversible antagonist of isoprostanes and prostanoids for diabetic complications; and EV-35, a bacterial type II topoisomerase inhibitor. Evolva Holding SA is based in Reinach, Switzerland.

108 Employees
Last Reported Date: 09/4/14

evolva holding sa (ADF) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: SFr.346.4K
Compensation as of Fiscal Year 2013.

evolva holding sa (ADF) Key Developments

Evolva and Valent BioSciences to Co-Develop Agricultural Bioactives

Evolva and Valent BioSciences Corporation (VBC), a subsidiary of Sumitomo Chemical Company, have signed an exclusive agreement to co-develop and commercialise a class of high-value active ingredients for use as next-generation agricultural bioactives. For competitive reasons, the ingredients are not being identified at this time. Bioactives are being used increasingly around the globe because they help growers improve crop yields without any negative effects to either human health or the environment. They are used in both organic and conventional agriculture and horticulture. Along with crop rotation and integrated pest management strategies, bioactives play an important role in sustainable farming. The collaboration will start by developing yeast strains that make the desired ingredients. Evolva has the primary responsibility for this phase while VBC will be responsible for commercialisation. The companies will work together on scale-up and manufacturing. The first products from the collaboration are expected to be launched in 4-5 years. Total spending on the project during the next five years is estimated at CHF 12-14 million. Evolva and VBC have agreed to split equally both the R&D costs and profits from active ingredient sales.

Evolva Holding SA., 2014 Earnings Call, Mar 31, 2015

Evolva Holding SA., 2014 Earnings Call, Mar 31, 2015

Evolva Announces Unaudited Earnings Results for the Year 2014; Provides Earnings Guidance for the Year 2015

Evolva announced unaudited earnings results for the year 2014. For the year, revenues in 2014 slightly exceeded CHF 10 million (in line with guidance), whilst the year-end cash position of CHF 60.7 million was higher than the CHF 50 million projected in November 2014. This positive deviation is primarily due to transactions related to the acquisition of Allylix in December: the USD 4 million investment by Cargill and the sale of 6 million shares to cover Allylix liabilities that was executed earlier than expected (in December 2014). After adjusting for the above two factors, cash at year-end was about CHF 52.5 million compared with guidance of CHF 50 million. Cash outflow from operations in 2014 developed in line with the November guidance (about CHF 20 million). For the year 2015, the company expects revenues to increase on 2014. Product related revenues will contribute for the first time, however a significant majority of revenues will still derive from partnerships. Due to investment in manufacturing and commercialization of key products, in particular stevia, resveratrol and nootkatone, operating cash outflow will increase in 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADF:GR €1.62 EUR -0.117

ADF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ADF.
View Industry Companies
 

Industry Analysis

ADF

Industry Average

Valuation ADF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 41.2x
Price/Book 3.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 45.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EVOLVA HOLDING SA, please visit www.evolva.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.